ArticleFrontiers in oncology2025
Hepatic epithelioid hemangioendothelioma, a rare liver tumor: a case report and review of the literature.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatic epithelioid hemangioendothelioma (HEHE) is classified as a rare, low-grade malignant neoplasm of vascular origin. This study presents a case report of a young female patient recently diagnosed with HEHE. A comprehensive review of the current understanding of HEHE is provided, along with the implementation of a novel combination treatment approach based on contemporary knowledge of this rare hepatic malignancy. Case: A 22-year-old female patient, with no prior medical history, underwent a routine health examination five months prior to presentation. Multiple space-occupying lesions in the liver were incidentally detected through ultrasound imaging, despite the patient being asymptomatic. Subsequent positron emission tomography-computed tomography (PET-CT) examination suggested the possibility of benign lesions. Recent follow-up examinations revealed no further progression of the lesions; however, a biopsy of the lesions confirmed the diagnosis of HEHE. Comprehensive imaging studies, including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), demonstrated scattered space-occupying lesions throughout the liver, with no evidence of distant metastasis. To minimize surgical trauma and preserve liver function, a multidisciplinary team was consulted, and a treatment plan was devised: liver resection in combination with microwave ablation of the lesions. The patient's postoperative recovery was uneventful, leading to successful hospital discharge. Conclusion: HEHE is characterized by its insidious onset and rarity, often presenting with multiple lesions at the time of clinical diagnosis. While liver transplantation may be considered the optimal treatment for multifocal HEHE, in cases where transplantation is not feasible, the combination of liver resection and microwave ablation of lesions may represent a safe and effective alternative therapeutic approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.